9价结合肺炎球菌疫苗在未接种加强剂量疫苗的人类免疫缺陷病毒感染儿童和未感染儿童中的长期免疫原性和疗效
Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
作者信息
Madhi Shabir A, Adrian Peter, Kuwanda Locadiah, Jassat Wasilla, Jones Stephanie, Little Tessa, Soininen Anu, Cutland Clare, Klugman Keith P
机构信息
University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa.
出版信息
Vaccine. 2007 Mar 22;25(13):2451-7. doi: 10.1016/j.vaccine.2006.09.019. Epub 2006 Sep 20.
The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.
在感染HIV和未感染HIV的儿童中研究了9价结合肺炎球菌疫苗的长期免疫原性和疫苗效力（VE）。在未感染HIV的儿童中，经过6.16年随访后，针对疫苗血清型侵袭性肺炎球菌疾病的疫苗效力持续存在（77.8%；95%可信区间34.4 - 92.5，相比2.3年随访后的83%），而在感染HIV的儿童中，该效力从65%降至38.8%（95%可信区间-7.8至65.2）。在5.3岁时，与感染HIV的疫苗接种者相比，未感染HIV的疫苗接种者针对所分析的疫苗血清型，血清型特异性抗体浓度≥0.2μg/ml的比例相同（血清型4、6B、14、19F）或更高（血清型9V、18C、23F）。
Zotero 插件